Surface-Modified Nanocarriers for Nose-to-Brain Delivery: From Bioadhesion to Targeting

Abstract

In the field of nasal drug delivery, nose-to-brain delivery is among the most fascinating applications, directly targeting the central nervous system, bypassing the blood brain barrier. Its benefits include dose lowering and direct brain distribution of potent drugs, ultimately reducing systemic side effects. Recently, nasal administration of insulin showed promising results in clinical trials for the treatment of Alzheimer’s disease. Nanomedicines could further contribute to making nose-to-brain delivery a reality. While not disregarding the need for devices enabling a formulation deposition in the nose’s upper part, surface modification of nanomedicines appears the key strategy to optimize drug delivery from the nasal cavity to the brain. In this review, nanomedicine delivery based on particle engineering exploiting surface electrostatic charges, mucoadhesive polymers, or chemical moieties targeting the nasal epithelium will be discussed and critically evaluated in relation to nose-to-brain delivery.

References 175

1. 1.

   Pozzoli M., Rogueda P., Zhu B., Smith T., Young P.M., Traini D., Sonvico F. Dry powder nasal drug delivery: Challenges, opportunities and a study of the commercial Teijin Puvlizer Rhinocort device and formulation. Drug Dev. Ind. Pharm. 2016;42:1660-1668.

   Not in our library10.3109/03639045.2016.1160110

2. 2.

   Pires A., Fortuna A., Alves G., Falcão A. Intranasal drug delivery: How, why and what for? J. Pharm. Pharm. Sci. 2009;12:288-311.

   Not in our library10.18433/j3nc79

3. 3.

   Chen Y., Liu L. Modern methods for delivery of drugs across the blood-brain barrier. Adv. Drug Deliv. Rev. 2012;64:640-665.

   Not in our library10.1016/j.addr.2011.11.010

4. 4.

   Gabathuler R. Approaches to transport therapeutic drugs across the blood-brain barrier to treat brain diseases. Neurobiol. Dis. 2010;37:48-57.

   Not in our library10.1016/j.nbd.2009.07.028

5. 5.

   Garcia-Garcia E., Gil S., Andrieux K., Desmaële D., Nicolas V., Taran F., Georgin D., Andreux J.P., Roux F., Couvreur P. A relevant in vitro rat model for the evaluation of blood-brain barrier translocation of nanoparticles. Cell. Mol. Life Sci. 2005;62:1400-1408.

   Not in our library10.1007/s00018-005-5094-3

6. 6.

   Alam M.I., Beg S., Samad A., Baboota S., Kohli K., Ali J., Ahuja A., Akbar M. Strategy for effective brain drug delivery. Eur. J. Pharm. Sci. 2010;40:385-403.

   Not in our library10.1016/j.ejps.2010.05.003

7. 7.

   Wong H.L., Wu X.Y., Bendayan R. Nanotechnological advances for the delivery of CNS therapeutics. Adv. Drug Deliv. Rev. 2012;64:686-700.

   Not in our library10.1016/j.addr.2011.10.007

8. 8.

   Costantino L., Boraschi D. Is there a clinical future for polymeric nanoparticles as brain-targeting drug delivery agents? Drug Discov. Today. 2012;17:367-378.

   Not in our library10.1016/j.drudis.2011.10.028

9. 9.

   Pardeshi C.V., Belgamwar V.S. Direct nose to brain drug delivery via integrated nerve pathways bypassing the blood-brain barrier: An excellent platform for brain targeting. Expert Opin. Drug Deliv. 2013;10:957-972.

   Not in our library10.1517/17425247.2013.790887

10. 10.

    Thorne R.G., Pronk G.J., Padmanabhan V., Frey W.H. Delivery of insulin-like growth factor-I to the rat brain and spinal cord along olfactory and trigeminal pathways following intranasal administration. Neuroscience. 2004;127:481-496.

    Not in our library10.1016/j.neuroscience.2004.05.029

11. 11.
    Intranasal Treatment of Central Nervous System Dysfunction in Humans · 2012

    No notice
12. 12.

    Illum L. Transport of drugs from the nasal cavity to the central nervous system. Eur. J. Pharm. Sci. 2000;11:1-18.

    Not in our library10.1016/s0928-0987(00)00087-7

13. 13.

    Ying W. The nose may help the brain: Intranasal drug delivery for treating neurological diseases. Future Neurol. 2008;3:1-4.

    Not in our library10.2217/14796708.3.1.1

14. 14.

    Dhuria S.V. Intranasal delivery to the central nervous system: Mechanisms and experimental considerations. J. Pharm. Sci. 2010;99:1654-1673.

    Not in our library10.1002/jps.21924

15. 15.

    Samaridou E., Alonso M.J. Nose-to-brain peptide delivery—The potential of nanotechnology. Bioorg. Med. Chem. 2018.

    Not in our library10.1016/j.bmc.2017.11.001

16. 16.

    Comfort C., Garrastazu G., Pozzoli M., Sonvico F. Opportunities and Challenges for the Nasal Administration of Nanoemulsions. Curr. Top. Med. Chem. 2015;15:356-368.

    Not in our library10.2174/1568026615666150108144655

17. 17.

    Cady R. A novel intranasal breath-powered delivery system for sumatriptan: A review of technology and clinical application of the investigational product AVP-825 in the treatment of migraine. Expert Opin. Drug Deliv. 2015;12:1565-1577.

    Not in our library10.1517/17425247.2015.1060959

18. 18.

    Yamada K., Hasegawa M., Kametani S., Ito S. Nose-to-brain delivery of TS-002, prostaglandin D2 analogue. J. Drug Target. 2007;15:59-66.

    Not in our library10.1080/10611860601029496

19. 19.

    Colombo G., Lorenzini L., Zironi E., Galligioni V., Sonvico F., Sonvico F., Balducci A.G., Balducci A.G., Pagliuca G., Giuliani A., et al. Brain distribution of ribavirin after intranasal administration. Antivir. Res. 2011;92:408-414.

    Not in our library10.1016/j.antiviral.2011.09.012

20. 20.
    Formulations for Intranasal Delivery of Pharmacological Agents to Combat Brain Disease: A New Opportunity to Tackle GBM? · 2013

    No notice
21. 21.

    Peterson A., Bansal A., Hofman F., Chen T.C., Zada G. A systematic review of inhaled intranasal therapy for central nervous system neoplasms: An emerging therapeutic option. J. Neurooncol. 2014;116:437-446.

    Not in our library10.1007/s11060-013-1346-5

22. 22.

    Duchi S., Ovadia H., Touitou E. Nasal administration of drugs as a new non-invasive strategy for efficient treatment of multiple sclerosis. J. Neuroimmunol. 2013;258:32-40.

    Not in our library10.1016/j.jneuroim.2013.02.013

23. 23.

    Kulkarni J.A., Avachat A.M. Pharmacodynamic and pharmacokinetic investigation of cyclodextrin-mediated asenapine maleate in situ nasal gel for improved bioavailability. Drug Dev. Ind. Pharm. 2017;43:234-245.

    Not in our library10.1080/03639045.2016.1236808

24. 24.

    Aly A.E.-E., Waszczak B.L. Intranasal gene delivery for treating Parkinsons disease: Overcoming the blood-brain barrier. Expert Opin. Drug Deliv. 2015;12:1923-1941.

    Not in our library10.1517/17425247.2015.1069815

25. 25.

    Sood S., Jain K., Gowthamarajan K. Intranasal therapeutic strategies for management of Alzheimer’s disease. J. Drug Target. 2014;22:279-294.

    Not in our library10.3109/1061186x.2013.876644

26. 26.

    Yuan D., Yi X., Zhao Y., Poon C.-D., Bullock K.M., Hansen K.M., Salameh T.S., Farr S.A., Banks W.A., Kabanov A.V. Intranasal delivery of N-terminal modified leptin-pluronic conjugate for treatment of obesity. J. Control. Release. 2017;263:172-184.

    Not in our library10.1016/j.jconrel.2017.03.029

27. 27.

    Arora P., Sharma S., Garg S. Permeability issues in nasal drug delivery. Drug Discov. Today. 2002;7:967-975.

    Not in our library10.1016/s1359-6446(02)02452-2

28. 28.

    Merkus F.W.H.M., van den Berg M.P. Can Nasal Drug Delivery Bypass the Blood-Brain Barrier? Drugs R & D. 2007;8:133-144.

    Not in our library10.2165/00126839-200708030-00001

29. 29.

    Illum L. Is nose-to-brain transport of drugs in man a reality? J. Pharm. Pharmacol. 2004;56:3-17.

    Not in our library10.1211/0022357022539

30. 30.
    Nasal drug delivery devices: characteristics and performance in a clinical perspective—a review · 2012

    No notice
31. 31.

    Kozlovskaya L., Stepensky D. Quantitative analysis of drug delivery to the brain via nasal route. J. Control. Release. 2014;189:133-140.

    Not in our library10.1016/j.jconrel.2014.06.053

32. 32.

    Ruigrok M.J.R., de Lange E.C.M. Emerging Insights for Translational Pharmacokinetic and Pharmacokinetic-Pharmacodynamic Studies: Towards Prediction of Nose-to-Brain Transport in Humans. AAPS J. 2015;17:493-505.

    Not in our library10.1208/s12248-015-9724-x

33. 33.

    Reger M.A., Watson G.S., Green P.S., Wilkinson C.W., Baker L.D., Cholerton B., Fishel M.A., Plymate S.R., Breitner J.C.S., DeGroodt W., et al. Intranasal insulin improves cognition and modulates beta-amyloid in early AD. Neurology. 2008;70:440-448.

    Not in our library10.1212/01.wnl.0000265401.62434.36

34. 34.

    Craft S., Claxton A., Baker L.D., Hanson A.J., Cholerton B., Trittschuh E.H., Dahl D., Caulder E., Neth B., Montine T.J., et al. Effects of Regular and Long-Acting Insulin on Cognition and Alzheimer’s Disease Biomarkers: A Pilot Clinical Trial. J. Alzheimers Dis. 2017;57:1325-1334.

    Not in our library10.3233/jad-161256

35. 35.

    Quintana D.S., Westlye L.T., Hope S., Nærland T., Elvsåshagen T., Dørum E., Rustan Ø., Valstad M., Rezvaya L., Lishaugen H., et al. Dose-dependent social-cognitive effects of intranasal oxytocin delivered with novel Breath Powered device in adults with autism spectrum disorder: A randomized placebo-controlled double-blind crossover trial. Transl. Psychiatry. 2017;7:e1136.

    Not in our library10.1038/tp.2017.103

36. 36.
    Helping oxytocin deliver: considerations in the development of oxytocin-based therapeutics for brain disorders · 2013

    No notice
37. 37.

    Gozes I., Morimoto B.H., Tiong J., Fox A., Sutherland K., Dangoor D., Holser-Cochav M., Vered K., Newton P., Aisen P.S., et al. NAP: Research and development of a peptide derived from activity-dependent neuroprotective protein (ADNP). CNS Drug Rev. 2005;11:353-368.

    Not in our library10.1111/j.1527-3458.2005.tb00053.x

38. 38.

    Morimoto B.H., Schmechel D., Hirman J., Blackwell A., Keith J., Gold M. A double-blind, placebo-controlled, ascending-dose, randomized study to evaluate the safety, tolerability and effects on cognition of AL-108 after 12 weeks of intranasal administration in subjects with mild cognitive impairment. Dement. Geriatr. Cogn. Disord. 2013;35:325-336.

    Not in our library10.1159/000348347

39. 39.

    Boxer A.L., Lang A.E., Grossman M., Knopman D.S., Miller B.L., Schneider L.S., Doody R.S., Lees A., Golbe L.I., Williams D.R., et al. AL-108-231 Investigators Davunetide in patients with progressive supranuclear palsy: A randomised, double-blind, placebo-controlled phase 2/3 trial. Lancet Neurol. 2014;13:676-685.

    Not in our library10.1016/s1474-4422(14)70088-2

40. 40.

    Landis M.S., Boyden T., Pegg S. Nasal-to-CNS drug delivery: Where are we now and where are we heading? An industrial perspective. Ther. Deliv. 2012;3:195-208.

    Not in our library10.4155/tde.11.149

Cited by papers we hold 3

• Nanotherapeutics for Nose-to-Brain Drug Delivery: An Approach to Bypass the Blood Brain Barrier · 2021
  No notice
• Endo-lysosomal dysregulations and late-onset Alzheimer’s disease: impact of genetic risk factors · 2019
  No notice
• Nanoemulsions for “Nose-to-Brain” Drug Delivery · 2019
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.